NCT04298060View on ClinicalTrials.gov

DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)

PHASE2UnknownINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

July 31, 2020

Primary Completion Date

March 31, 2021

Study Completion Date

September 30, 2022

Conditions
Influenza InfectionSAD-RV Infection and COVID-19
Interventions
DRUG

DAS181

SD (4.5mg/day), HD (9mg/day)

DRUG

Placebo

Placebo 0mg/day

Trial Locations (1)

Unknown

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

Sponsors
All Listed Sponsors
lead

Ansun Biopharma, Inc.

INDUSTRY